Nanomedicine News and Research

RSS

Scientists establish link between autoimmune diseases and nanoparticles

New groundbreaking research by scientists at Trinity College Dublin has found that exposure to nanoparticles can have a serious impact on health, linking it to rheumatoid arthritis and the development of other serious autoimmune diseases.

12 Jun 2012

Nanocontainers can fight against atherosclerosis

In Switzerland, more than 20,000 people (37% of all deaths) die of cardiovascular disease caused by atherosclerosis each year. Treatment options are currently available to people who suffer from the disease but no drug can target solely the diseased areas, often leading to generalized side effects.

11 Jun 2012

New nanomedicine cancer treatments promise to reduce severity of side effects

A new generation of cancer treatments based on nanotechnology is making its way out of the laboratory and into the clinic with the promise of targeting cancer cells while steering clear of healthy tissue, according to the current edition of Chemical & Engineering News.

7 Jun 2012

Biochemiresistor can quickly detect small traces of contaminants in liquids

A whole new class of biosensor that can detect exceptionally small traces of contaminants in liquids in just 40 minutes has been developed by a UNSW-led team of researchers.

1 Jun 2012

IntelliCell enters sponsored research agreement with ICERM

IntelliCell BioSciences, Inc. announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM) at the University of Florida.

23 May 2012

First study to test safety of quantum dots in primates

A pioneering study to gauge the toxicity of quantum dots in primates has found the tiny crystals to be safe over a one-year period, a hopeful outcome for doctors and scientists seeking new ways to battle diseases like cancer through nanomedicine.

21 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

Nanoparticle carriers successfully deliver therapeutic doses of cancer drug

Current nanomedicine research has focused on the delivery of established and novel therapeutics. But a UNC team is taking a different approach. They developed nanoparticle carriers to successfully deliver therapeutic doses of a cancer drug that had previously failed clinical development due to pharmacologic challenges.

3 May 2012

New bio-inspired approach can synthesize polymers

A new bio-inspired approach to synthesising polymers will offer unprecedented control over the final polymer structure and yield advances in nanomedicine, researchers say.

3 May 2012

Nano-devices cross blood-brain barrier to deliver drug to treat cerebral palsy

A team of scientists from Johns Hopkins and elsewhere have developed nano-devices that successfully cross the brain-blood barrier and deliver a drug that tames brain-damaging inflammation in rabbits with cerebral palsy.

23 Apr 2012

Hydrophilic carbon cluster HADES can selectively kill brain cancer cells

Nanomedicine researchers at the Methodist Neurological Institute and Rice University have developed a way to selectively kill brain cancer cells by using a tiny syringe to deliver a combination of chemotherapy drugs directly into the cells. These findings will be published in the April 24 issue of the American Chemical Society journal ACS Nano.

17 Apr 2012

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

BIND announces data from BIND-014 Phase 1 trials on prostate cancer

Nanomedicine research at the David H. Koch Institute for Integrative Cancer Research at MIT funded by a $5 million grant from the Prostate Cancer Foundation (PCF) has delivered the first nanomedicine shown to successfully target prostate cancer cells and deliver docetaxel chemotherapy in high concentrations in Phase I clinical trials.

5 Apr 2012

BIND presents results from BIND-014 Phase 1 trial on solid tumors at AACR 2012

BIND Biosciences, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted therapeutics called Accurins, announced today the presentation of late-breaker clinical data for BIND-014, the lead drug candidate within a new class of targeted therapeutics that are programmed to concentrate at tumors, at the American Association for Cancer Research (AACR) 2012 Annual Meeting.

5 Apr 2012

Gold nanoparticles used to introduce chemical residues into the immune system

Developing a drug or vaccine requires a delicate balancing act with the immune system. On one hand, medications need to escape detection by the immune system in order to perform their function. But vaccinations - de-activated versions of a disease or virus - need to do the reverse. They prompt the immune system to create protective antibodies.

27 Mar 2012

Arrowhead, Axolabs enter into RNAi therapeutics strategic agreement

Arrowhead Research Corporation, a nanomedicine company with development programs in RNAi therapeutics and obesity, and Axolabs GmbH, a custom research organization offering preclinical solutions and consultancy in the field of oligonucleotide therapeutics, today announced that they have entered into a Strategic Alliance and Master Services Agreement.

5 Mar 2012

Researchers create prostate cancer drug delivery system

Honing chemotherapy delivery to cancer cells is a challenge for many researchers. Getting the cancer cells to take the chemotherapy "bait" is a greater challenge. But perhaps such a challenge has not been met with greater success than by the nanotechnology research team of Omid Farokhzad, MD, Brigham and Women's Hospital (BWH) Department of Anesthesiology Perioperative and Pain Medicine and Research.

10 Jan 2012

Arrowhead receives FDA IND approval for Adipotide obesity drug

Arrowhead Research Corporation, a nanomedicine company with development programs in oncology and obesity, today announced that the Investigational New Drug Application (IND) for its first obesity drug candidate, Adipotide, was accepted by the U.S. Food and Drug Administration allowing the initiation of a clinical trial to test the safety of the compound.

5 Jan 2012

Scientists devise a way to reduce side effects of lung cancer therapy

Scientists may have a way to double the efficacy and reduce the side effects of radiation therapy.

17 Dec 2011

Nanosized metallic particles on implant surfaces may reduce risk of rejection

Coating the surface of an implant such as a new hip or pacemaker with nanosized metallic particles reduces the risk of rejection, and researchers at the University of Gothenburg, Sweden, can now explain why: they fool the innate immune system.

30 Nov 2011